KR102358878B1 - 중간뇌 도파민(mda) 뉴런의 시험관내 분화 방법 - Google Patents

중간뇌 도파민(mda) 뉴런의 시험관내 분화 방법 Download PDF

Info

Publication number
KR102358878B1
KR102358878B1 KR1020177037050A KR20177037050A KR102358878B1 KR 102358878 B1 KR102358878 B1 KR 102358878B1 KR 1020177037050 A KR1020177037050 A KR 1020177037050A KR 20177037050 A KR20177037050 A KR 20177037050A KR 102358878 B1 KR102358878 B1 KR 102358878B1
Authority
KR
South Korea
Prior art keywords
cells
cell
signaling
activator
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177037050A
Other languages
English (en)
Korean (ko)
Other versions
KR20180014743A (ko
Inventor
로렌즈 스튜더
스테판 이리온
마크 도미시마
손자 크릭스
Original Assignee
메모리얼 슬로안 케터링 캔서 센터
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메모리얼 슬로안 케터링 캔서 센터 filed Critical 메모리얼 슬로안 케터링 캔서 센터
Priority to KR1020227003399A priority Critical patent/KR102679619B1/ko
Publication of KR20180014743A publication Critical patent/KR20180014743A/ko
Application granted granted Critical
Publication of KR102358878B1 publication Critical patent/KR102358878B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/30—Nerves; Brain; Eyes; Corneal cells; Cerebrospinal fluid; Neuronal stem cells; Neuronal precursor cells; Glial cells; Oligodendrocytes; Schwann cells; Astroglia; Astrocytes; Choroid plexus; Spinal cord tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/155—Bone morphogenic proteins [BMP]; Osteogenins; Osteogenic factor; Bone inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/16—Activin; Inhibin; Mullerian inhibiting substance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020177037050A 2015-06-01 2016-06-01 중간뇌 도파민(mda) 뉴런의 시험관내 분화 방법 Active KR102358878B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227003399A KR102679619B1 (ko) 2015-06-01 2016-06-01 중간뇌 도파민(mda) 뉴런의 시험관내 분화 방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562169379P 2015-06-01 2015-06-01
US201562169444P 2015-06-01 2015-06-01
US62/169,379 2015-06-01
US62/169,444 2015-06-01
PCT/US2016/035312 WO2016196661A1 (en) 2015-06-01 2016-06-01 Methods of in vitro differentiation of midbrain dopamine (mda) neurons

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227003399A Division KR102679619B1 (ko) 2015-06-01 2016-06-01 중간뇌 도파민(mda) 뉴런의 시험관내 분화 방법

Publications (2)

Publication Number Publication Date
KR20180014743A KR20180014743A (ko) 2018-02-09
KR102358878B1 true KR102358878B1 (ko) 2022-02-08

Family

ID=57441792

Family Applications (4)

Application Number Title Priority Date Filing Date
KR1020177037050A Active KR102358878B1 (ko) 2015-06-01 2016-06-01 중간뇌 도파민(mda) 뉴런의 시험관내 분화 방법
KR1020227003399A Active KR102679619B1 (ko) 2015-06-01 2016-06-01 중간뇌 도파민(mda) 뉴런의 시험관내 분화 방법
KR1020257025403A Pending KR20250118858A (ko) 2015-06-01 2016-06-01 중간뇌 도파민(mda) 뉴런의 시험관내 분화 방법
KR1020247021208A Active KR102841407B1 (ko) 2015-06-01 2016-06-01 중간뇌 도파민(mda) 뉴런의 시험관내 분화 방법

Family Applications After (3)

Application Number Title Priority Date Filing Date
KR1020227003399A Active KR102679619B1 (ko) 2015-06-01 2016-06-01 중간뇌 도파민(mda) 뉴런의 시험관내 분화 방법
KR1020257025403A Pending KR20250118858A (ko) 2015-06-01 2016-06-01 중간뇌 도파민(mda) 뉴런의 시험관내 분화 방법
KR1020247021208A Active KR102841407B1 (ko) 2015-06-01 2016-06-01 중간뇌 도파민(mda) 뉴런의 시험관내 분화 방법

Country Status (18)

Country Link
US (3) US10858625B2 (cg-RX-API-DMAC7.html)
EP (3) EP3303564B1 (cg-RX-API-DMAC7.html)
JP (5) JP6974180B2 (cg-RX-API-DMAC7.html)
KR (4) KR102358878B1 (cg-RX-API-DMAC7.html)
AU (3) AU2016270793B2 (cg-RX-API-DMAC7.html)
CY (1) CY1125423T1 (cg-RX-API-DMAC7.html)
DK (2) DK4070803T3 (cg-RX-API-DMAC7.html)
ES (2) ES3057638T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20220482T1 (cg-RX-API-DMAC7.html)
HU (1) HUE058258T2 (cg-RX-API-DMAC7.html)
IL (4) IL291532B2 (cg-RX-API-DMAC7.html)
LT (1) LT3303564T (cg-RX-API-DMAC7.html)
PL (1) PL3303564T3 (cg-RX-API-DMAC7.html)
PT (2) PT4070803T (cg-RX-API-DMAC7.html)
RS (1) RS63157B1 (cg-RX-API-DMAC7.html)
SI (1) SI3303564T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200263T1 (cg-RX-API-DMAC7.html)
WO (1) WO2016196661A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3280426B1 (en) * 2015-04-09 2025-06-25 Biolamina AB Methods and compositions for producing stem cell derived dopaminergic cells for use in treatment of neurodegenerative diseases
WO2016196661A1 (en) * 2015-06-01 2016-12-08 Memorial Sloan-Kettering Cancer Center Methods of in vitro differentiation of midbrain dopamine (mda) neurons
JP7523885B2 (ja) 2016-02-05 2024-07-29 メモリアル スローン ケタリング キャンサー センター 幹細胞由来外胚葉系統前駆体を分化する方法
AU2017313065B2 (en) * 2016-08-16 2021-06-24 Fujifilm Cellular Dynamics Inc. Methods for differentiating pluripotent cells
CN110868853A (zh) * 2017-04-26 2020-03-06 纪念斯隆-凯特琳癌症中心 即用型冷冻保存细胞
EP3655774B1 (en) 2017-07-17 2024-09-25 Miltenyi Biotec B.V. & Co. KG A method for single cell protein expression profiling of floorplate mesencephalic dopaminergic progenitor cells
US20200248139A1 (en) * 2017-08-08 2020-08-06 Regents Of The University Of Minnesota Methods for generating and using organoids and cells thereof
WO2020132055A1 (en) 2018-12-19 2020-06-25 Regents Of The University Of Minnesota Methods for generating and using organoids and tissue therein
EP3972617A4 (en) * 2019-05-23 2023-06-07 The McLean Hospital Corporation AUTOLOGOUS CELL REPLACEMENT THERAPY FOR PARKINSON'S DISEASE
CN115485371A (zh) 2019-07-25 2022-12-16 斯克里普斯研究学院 鉴定多巴胺能神经元和祖细胞的方法
KR20220051388A (ko) * 2019-08-29 2022-04-26 메모리얼 슬로안 케터링 캔서 센터 중간뇌 도파민 뉴런의 생성 및 단리 방법
US20230000923A1 (en) * 2019-09-20 2023-01-05 Korea Research Institute Of Bioscience And Biotechnology Production method for induced dopaminergic neuronal progenitors, using direct reprogramming
EP4125961A1 (en) 2020-03-25 2023-02-08 Sana Biotechnology, Inc. Hypoimmunogenic neural cells for the treatment of neurological disorders and conditions
US20230165909A1 (en) 2020-04-21 2023-06-01 Aspen Neuroscience, Inc. Gene editing of lrrk2 in stem cells and method of use of cells differentiated therefrom
WO2021216622A1 (en) 2020-04-21 2021-10-28 Aspen Neuroscience, Inc. Gene editing of gba1 in stem cells and method of use of cells differentiated therefrom
CN116635047A (zh) * 2020-06-26 2023-08-22 米纳瓦生物技术公司 用于从多能干细胞衍生多巴胺能神经元的方法
EP4171592A4 (en) * 2020-06-26 2024-07-31 Minerva Biotechnologies Corporation Methods for deriving dopaminergic neurons from pluripotent stem cells
CN114292814A (zh) * 2020-09-22 2022-04-08 上海跃赛生物科技有限公司 一种多能干细胞分化为中脑黒质多巴胺能神经细胞的方法
EP4319876A1 (en) * 2021-04-07 2024-02-14 Fujifilm Cellular Dynamics, Inc. Dopaminergic precursor cells and methods of use
US20250082686A1 (en) 2021-07-21 2025-03-13 Aspen Neuroscience, Inc. Aav-based modulation of gba1 and related compositions and uses thereof
WO2023004366A1 (en) 2021-07-21 2023-01-26 Aspen Neuroscience, Inc. Transposon-based modulation of gba1 and related compositions and uses thereof
EP4413119A1 (en) 2021-11-12 2024-08-14 Axent Biosciences Inc. Methods for production of functional neurons
CN119384700A (zh) 2022-04-15 2025-01-28 艾斯本神经科学公司 细胞分化状态的分类方法和分化细胞的相关组合物
WO2024259119A2 (en) * 2023-06-13 2024-12-19 Aspen Neuroscience, Inc. Methods for differentiating dopaminergic neurons from stem cells
CN117448271B (zh) * 2023-12-22 2024-07-16 上海元戊医学技术有限公司 一种诱导多能干细胞分化为中脑多巴胺能神经前体细胞的方法
AU2025217196A1 (en) 2024-01-31 2026-07-09 Bluerock Therapeutics Lp Igfbp2 in cell culture
WO2025252180A1 (zh) * 2024-06-05 2025-12-11 中国科学院脑科学与智能技术卓越创新中心 中脑多巴胺能祖细胞群的体外制备方法
US20250382572A1 (en) * 2024-06-13 2025-12-18 Aspen Neuroscience, Inc. Automated methods for differentiating dopaminergic neurons from stem cells
WO2026006245A1 (en) 2024-06-25 2026-01-02 Bluerock Therapeutics Lp Three-dimensional culturing of pluripotent stem cells for improved differentiability

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013067362A1 (en) 2011-11-04 2013-05-10 Memorial Sloan-Kettering Cancer Center Midbrain dopamine (da) neurons for engraftment
JP2014110790A (ja) 2000-05-17 2014-06-19 Asterious Biotherapeutics Inc 神経前駆細胞の集団
WO2015020234A1 (ja) 2013-08-06 2015-02-12 武田薬品工業株式会社 ドパミン神経細胞の製造方法
KR101696874B1 (ko) 2013-07-31 2017-01-16 한국생명공학연구원 직접 리프로그래밍을 통한 유도 도파민성 전구세포 제조방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4703300A (en) 1999-05-06 2000-11-21 Mount Sinai School Of Medicine Of The City University Of New York, The Dna-based steganography
US20090226536A1 (en) * 2004-09-02 2009-09-10 Arenas Ernesto A Methods and materials relating to enhanced production of dopamine neurons
CA2589063C (en) * 2004-12-23 2016-08-09 DePuy Synthes Products, Inc. Treatment of parkinson's disease and related disorders using postpartum derived cells
GEP20135796B (en) 2006-03-07 2013-04-10 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation
US8535719B2 (en) 2006-07-07 2013-09-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biohybrid elastomeric scaffolds and methods of use thereof
US8642334B2 (en) 2009-02-17 2014-02-04 Memorial Sloan Kettering Cancer Center Methods of neural conversion of human embryonic stem cells
ES2747803T3 (es) 2010-05-25 2020-03-11 Memorial Sloan Kettering Cancer Center Método de diferenciación a nociceptores de células madre embrionarias humanas y sus usos
US20110296542A1 (en) 2010-05-28 2011-12-01 Kevin Ka-Wang Wang Exogenous matrix-supported topical application of stem cells to organ surface
WO2013188744A1 (en) 2012-06-15 2013-12-19 Baylor College Of Medicine Perineurium derived adult stem cells and methods of use
JP6756610B2 (ja) 2013-04-26 2020-09-16 メモリアル スローン ケタリング キャンサー センター 多分化能細胞および多能性細胞の分化を方向付けることによって発生させる皮質介在ニューロンおよびその他のニューロン細胞
CN121136933A (zh) 2013-09-05 2025-12-16 国立大学法人京都大学 由多能干细胞制造产多巴胺神经前体细胞的方法、产多巴胺神经前体细胞、帕金森病治疗剂和试剂盒
EP3071685B1 (en) 2013-11-21 2026-07-29 Memorial Sloan-Kettering Cancer Center Specification of functional cranial placode derivatives from human pluripotent stem cells
US9694036B2 (en) * 2014-03-21 2017-07-04 Cellular Dynamics International, Inc. Production of midbrain dopaminergic neurons and methods for the use thereof
WO2016196661A1 (en) * 2015-06-01 2016-12-08 Memorial Sloan-Kettering Cancer Center Methods of in vitro differentiation of midbrain dopamine (mda) neurons

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014110790A (ja) 2000-05-17 2014-06-19 Asterious Biotherapeutics Inc 神経前駆細胞の集団
WO2013067362A1 (en) 2011-11-04 2013-05-10 Memorial Sloan-Kettering Cancer Center Midbrain dopamine (da) neurons for engraftment
JP2014532440A (ja) 2011-11-04 2014-12-08 メモリアル スローン−ケタリング キャンサー センター 移植用中脳ドーパミン(da)ニューロン
KR101696874B1 (ko) 2013-07-31 2017-01-16 한국생명공학연구원 직접 리프로그래밍을 통한 유도 도파민성 전구세포 제조방법
WO2015020234A1 (ja) 2013-08-06 2015-02-12 武田薬品工業株式会社 ドパミン神経細胞の製造方法

Also Published As

Publication number Publication date
EP3303564A1 (en) 2018-04-11
CY1125423T1 (el) 2024-12-13
IL291532B2 (en) 2024-12-01
US20210123018A1 (en) 2021-04-29
SMT202200263T1 (it) 2022-07-21
EP4079314B1 (en) 2025-10-29
HUE058258T2 (hu) 2022-07-28
PL3303564T3 (pl) 2022-05-09
PT3303564T (pt) 2022-06-02
JP6974180B2 (ja) 2021-12-01
AU2016270793A1 (en) 2017-12-14
DK3303564T3 (da) 2022-04-04
EP3303564A4 (en) 2018-10-31
IL313799B1 (en) 2025-05-01
PT4070803T (pt) 2026-01-08
IL313799B2 (en) 2025-09-01
JP7737787B2 (ja) 2025-09-11
ES2910032T3 (es) 2022-05-11
AU2016270793B2 (en) 2022-06-09
JP2023181494A (ja) 2023-12-21
EP4079314A1 (en) 2022-10-26
EP3303564B1 (en) 2022-02-23
KR20220020416A (ko) 2022-02-18
AU2026200680A1 (en) 2026-02-19
AU2022228216B2 (en) 2026-02-19
IL291532A (en) 2022-05-01
ES3057638T3 (en) 2026-03-03
US10858625B2 (en) 2020-12-08
KR102679619B1 (ko) 2024-07-01
KR102841407B1 (ko) 2025-08-01
EP4070803A1 (en) 2022-10-12
LT3303564T (lt) 2022-05-10
DK4070803T3 (da) 2026-01-12
IL320440A (en) 2025-06-01
JP2026015509A (ja) 2026-01-29
IL291532B1 (en) 2024-08-01
CA2987617A1 (en) 2016-12-08
JP2020146060A (ja) 2020-09-17
KR20180014743A (ko) 2018-02-09
JP2022031961A (ja) 2022-02-22
IL255992A (en) 2018-01-31
SI3303564T1 (sl) 2022-07-29
EP4070803B1 (en) 2025-10-08
JP2018522538A (ja) 2018-08-16
IL255992B (en) 2022-04-01
US20240400987A1 (en) 2024-12-05
KR20250118858A (ko) 2025-08-06
KR20240101884A (ko) 2024-07-02
WO2016196661A1 (en) 2016-12-08
HRP20220482T1 (hr) 2022-07-08
AU2022228216A1 (en) 2022-10-06
RS63157B1 (sr) 2022-05-31
US20180094242A1 (en) 2018-04-05
IL313799A (en) 2024-08-01
US12084679B2 (en) 2024-09-10

Similar Documents

Publication Publication Date Title
US20240400987A1 (en) Methods of in vitro differentiation of midbrain dopamine (mda) neurons
CN114650836B (zh) 中脑多巴胺神经元的产生和分离方法
KR20220088800A (ko) 만능 세포를 분화시키는 방법
HK40082714A (en) Methods of in vitro differentiation of midbrain dopamine (mda) neurons
HK40081864A (en) Methods of in vitro differentiation of midbrain dopamine (mda) neurons
CA2987617C (en) Methods of in vitro differentiation of midbrain dopamine (mda) neurons
HK40075940B (en) Methods of generating and isolating midbrain dopamine neurons

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5